Advanced Cancer
609
91
134
315
Key Insights
Highlights
Success Rate
84% trial completion
Published Results
77 trials with published results (13%)
Research Maturity
315 completed trials (52% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.9%
60 terminated out of 609 trials
84.0%
-2.5% vs benchmark
4%
26 trials in Phase 3/4
24%
77 of 315 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 315 completed trials
Clinical Trials (609)
A Study of PHN-012 in Patients With Advanced Solid Tumors
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
Psilocybin in Cancer Pain Study
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Primary Palliative Care - a Feasibility Cluster Trial
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy in Patients With Cancer-Related Celiac Pain
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
SLV-154 Treatment of Advanced Cancers
Personalized Neoantigen Peptide Vaccines for Solid Tumors
Community Health Worker Based Intervention to Improve Palliative Care
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
AST-021p Study in Advanced Solid Tumors
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Web-Based Advance Care Planning for Patients With Advanced Cancer
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer